BRPI0410071A - métodos para usar no diagnóstico e prognóstico da artrite em um paciente, para usar no monitoramento do curso da artrite em um paciente, para avaliar a eficácia de um tratamento para artrite em um paciente, para triar um composto capaz de inibir a artrite em um paciente e para tratar artrite em um paciente, e, molécula de sirna - Google Patents

métodos para usar no diagnóstico e prognóstico da artrite em um paciente, para usar no monitoramento do curso da artrite em um paciente, para avaliar a eficácia de um tratamento para artrite em um paciente, para triar um composto capaz de inibir a artrite em um paciente e para tratar artrite em um paciente, e, molécula de sirna

Info

Publication number
BRPI0410071A
BRPI0410071A BRPI0410071-9A BRPI0410071A BRPI0410071A BR PI0410071 A BRPI0410071 A BR PI0410071A BR PI0410071 A BRPI0410071 A BR PI0410071A BR PI0410071 A BRPI0410071 A BR PI0410071A
Authority
BR
Brazil
Prior art keywords
patient
arthritis
methods
monitoring
course
Prior art date
Application number
BRPI0410071-9A
Other languages
English (en)
Inventor
Edward R Lavallie
Lisa A Collins-Racie
Maya Arai
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0410071A publication Critical patent/BRPI0410071A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rehabilitation Therapy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"MéTODOS PARA USAR NO DIAGNóSTICO E PROGNóSTICO DA ARTRITE EM UM PACIENTE, PARA USAR NO MONITORAMENTO DO CURSO DA ARTRITE EM UM PACIENTE, PARA AVALIAR A EFICáCIA DE UM TRATAMENTO PARA ARTRITE EM UM PACIENTE, PARA TRIAR UM COMPOSTO CAPAZ DE INIBIR A ARTRITE EM UM PACIENTE E PARA TRATAR ARTRITE EM UM PACIENTE, E, MOLéCULA DE SIRNA". A presente invenção está fundamentada na verificação de que a expressão de <sym>PKC é aumentada nos tecidos de pacientes com artrite quando comparado com indivíduos normais. Conseqüentemente, a presente invenção fornece métodos de diagnosticar, prognosticar e monitorar o curso da artrite em um paciente com base na expressão de gene <sym>PKC aumentada em tecido artrítico. A presente invenção ainda fornece compostos que inibem a expressão de <sym>PKC para o uso como remédios no tratamento de artrite, incluindo, mas não limitado a, polinucleotídeos e polipeptídeos inibitórios, inibidores de moléculas pequenas e peptídeo. Além disso, a presente invenção fornece formulações farmacêuticas e vias de administração para tais remédios, assim como a métodos para avaliar a sua eficácia.
BRPI0410071-9A 2003-05-08 2004-05-10 métodos para usar no diagnóstico e prognóstico da artrite em um paciente, para usar no monitoramento do curso da artrite em um paciente, para avaliar a eficácia de um tratamento para artrite em um paciente, para triar um composto capaz de inibir a artrite em um paciente e para tratar artrite em um paciente, e, molécula de sirna BRPI0410071A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46898703P 2003-05-08 2003-05-08
US49127403P 2003-07-31 2003-07-31
PCT/US2004/014759 WO2004104217A2 (en) 2003-05-08 2004-05-10 Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases

Publications (1)

Publication Number Publication Date
BRPI0410071A true BRPI0410071A (pt) 2006-05-23

Family

ID=33479253

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410071-9A BRPI0410071A (pt) 2003-05-08 2004-05-10 métodos para usar no diagnóstico e prognóstico da artrite em um paciente, para usar no monitoramento do curso da artrite em um paciente, para avaliar a eficácia de um tratamento para artrite em um paciente, para triar um composto capaz de inibir a artrite em um paciente e para tratar artrite em um paciente, e, molécula de sirna

Country Status (9)

Country Link
US (2) US7638482B2 (pt)
EP (1) EP1629283A2 (pt)
JP (1) JP2007515940A (pt)
CN (1) CN1860371B (pt)
AU (1) AU2004242105B2 (pt)
BR (1) BRPI0410071A (pt)
CA (1) CA2525012A1 (pt)
MX (1) MXPA05011777A (pt)
WO (1) WO2004104217A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160062A1 (en) * 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
WO2006094014A2 (en) 2005-02-28 2006-09-08 The Regents Of The University Of California Methods for diagnosis and treatment of endometrial cancer
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
JP5911805B2 (ja) 2009-11-20 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ）

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3731293A (en) * 1992-02-24 1993-09-13 Smithkline Beecham Corporation Protein kinase c inhibitor
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US6235723B1 (en) * 1992-03-16 2001-05-22 Isis Pharmaceuticals , Inc. Antisense oligonucleotide modulation of human protein kinase C-δ expression
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6368831B1 (en) * 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
CN1158283C (zh) * 1998-12-17 2004-07-21 霍夫曼-拉罗奇有限公司 作为蛋白激酶抑制剂的4-和5-吡嗪基羟吲哚
AU5873000A (en) * 1999-06-24 2001-01-31 Pharmacia Corporation Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors forthe treatment of inflammation
ATE253918T1 (de) * 1999-12-08 2003-11-15 Centre Nat Rech Scient Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
ATE289511T1 (de) * 2000-12-18 2005-03-15 Meiji Dairies Corp Kavalactone als hemmer der tnf-alpha produktion

Also Published As

Publication number Publication date
CN1860371A (zh) 2006-11-08
US20040259136A1 (en) 2004-12-23
AU2004242105B2 (en) 2009-05-28
WO2004104217A2 (en) 2004-12-02
EP1629283A2 (en) 2006-03-01
US20100062448A1 (en) 2010-03-11
CA2525012A1 (en) 2004-12-02
MXPA05011777A (es) 2006-01-26
WO2004104217A3 (en) 2005-11-24
JP2007515940A (ja) 2007-06-21
AU2004242105A1 (en) 2004-12-02
US7638482B2 (en) 2009-12-29
CN1860371B (zh) 2010-11-24

Similar Documents

Publication Publication Date Title
Eriksen et al. Pain, quality of life and recovery after laparoscopic ventral hernia repair
Mackeprang et al. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients
Roujeau et al. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985
Roy Hysterical seizures
Jawhar et al. Tourniquet-induced ischaemia during total knee arthroplasty results in higher proteolytic activities within vastus medialis cells: a randomized clinical trial
Charo et al. Rapid dissemination of practice-changing information: a longitudinal analysis of real-world rates of minimally invasive radical hysterectomy before and after presentation of the LACC trial
Pawlak et al. Comparison of two different concepts of mesh and fixation technique in laparoscopic ventral hernia repair: a randomized controlled trial
Wang et al. Class I HDAC imaging using [3H] CI-994 autoradiography
BR0111473A (pt) Métodos para triar um indivìduo quanto a uma doença de armazenagem de glicogênio, para triar um indivìduo quanto à doença de pompe, para monitorar a condição clìnica de um indivìduo com doença de pompe, para estimar a eficácia de um regime terapêutico em um indivìduo com doença de pompe e para determinar a concentração de um oligossacarìdeo em uma amostra biológica
BRPI0410071A (pt) métodos para usar no diagnóstico e prognóstico da artrite em um paciente, para usar no monitoramento do curso da artrite em um paciente, para avaliar a eficácia de um tratamento para artrite em um paciente, para triar um composto capaz de inibir a artrite em um paciente e para tratar artrite em um paciente, e, molécula de sirna
Morrison et al. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson’s disease (MSPD)
Ahmedzai Quality-of-life research in the European palliative care setting
Tankisi et al. Early detection of evolving critical illness myopathy with muscle velocity recovery cycles
Miaskowski Women and pain
Öner et al. Predicting postoperative pain with neutrophil/lymphocyte ratio after arthroscopic rotator cuff repair
Ho et al. The effect of taking blood pressure lowering medication at night on cardiovascular disease risk. A systematic review
Liu et al. High-dose methotrexate (HD-MTX) used as an adjunct with other chemotherapeutics for the treatment of osteosarcoma
Carou et al. Clinical profile, level of affection and therapeutic management of patients with osteoarthritis in primary care: the Spanish multicenter study EVALÚA
Fullerton et al. Advanced age attenuates the antihyperalgesic effect of morphine and decreases μ-opioid receptor expression and binding in the rat midbrain periaqueductal gray in male and female rats
AU2014308704B2 (en) Multiple myeloma treatment
Savage et al. Giant cell tumor of tendon sheath (localized nodular tenosynovitis)
Binder et al. Diltiazem-induced psychosis and a possible diltiazem-lithium interaction
Ban et al. Comparison of three concentrations of simplex lidocaine in local anesthesia for inguinal hernia mesh-repairs
BR0318166A (pt) uso de uma substáncia para detectar sgk1, kit para essa detecção, bem como composição farmacêutica que inibe ou ativa a sua expressão e/ou função
Virit et al. Lack of pain in schizophrenia: a patient whose arm was burned and amputated

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.